Your browser is no longer supported. Please, upgrade your browser.
Settings
PTLA Portola Pharmaceuticals, Inc. daily Stock Chart
PTLA [NASD]
Portola Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.05 Insider Own2.58% Shs Outstand56.51M Perf Week0.99%
Market Cap1.45B Forward P/E- EPS next Y-3.74 Insider Trans0.00% Shs Float56.23M Perf Month39.53%
Income-281.30M PEG- EPS next Q-1.04 Inst Own94.30% Short Float9.10% Perf Quarter25.01%
Sales26.20M P/S55.19 EPS this Y-36.60% Inst Trans0.27% Short Ratio4.63 Perf Half Y13.99%
Book/sh4.19 P/B6.11 EPS next Y22.70% ROA-66.50% Target Price27.87 Perf Year-26.68%
Cash/sh4.86 P/C5.27 EPS next 5Y- ROE-83.00% 52W Range15.68 - 38.32 Perf YTD14.04%
Dividend- P/FCF- EPS past 5Y23.60% ROI-53.10% 52W High-33.40% Beta1.21
Dividend %- Quick Ratio6.40 Sales past 5Y-19.30% Gross Margin- 52W Low62.77% ATR1.33
Employees137 Current Ratio6.40 Sales Q/Q220.70% Oper. Margin- RSI (14)64.45 Volatility5.85% 7.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-56.70% Profit Margin- Rel Volume0.43 Prev Close25.59
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume1.10M Price25.52
Recom2.00 SMA209.30% SMA5025.25% SMA20012.35% Volume29,671 Change-0.26%
Jan-03-17Upgrade Citigroup Neutral → Buy
Dec-27-16Reiterated Credit Suisse Outperform $20 → $29
Aug-19-16Downgrade Citigroup Buy → Neutral
May-31-16Downgrade Credit Suisse Outperform → Neutral $33 → $30
Mar-28-16Reiterated Credit Suisse Outperform $47 → $34
Mar-28-16Downgrade Goldman Buy → Neutral $65 → $30
Dec-18-15Initiated Goldman Buy
Jan-13-17 10:41AM  Why Portola Pharmaceuticals Crashed 56.4% In 2016 at Motley Fool
09:23AM  Biotech Premarket Movers: SGMO, IPXL, PTLA
Jan-12-17 03:54PM  3 Little-Known Pharmaceutical Companies to Put on Your Radar at Motley Fool
Jan-10-17 08:53AM  2 Top Stocks in Biotech at Motley Fool
Jan-03-17 05:41PM  My Worst Predictions for Biotech in 2016 at Motley Fool
08:00AM  Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017 GlobeNewswire
07:36AM  Portola Pharma upgraded by Citigroup
Dec-28-16 01:34PM  [$$] Portola Pharmaceuticals' Pivotal Year at Barrons.com
Dec-27-16 11:00AM  Biotech Poised for Rebound -9.10%
09:07AM  Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
Dec-23-16 05:35PM  Why Portola Pharmaceuticals Inc Stock Surged Higher Today at Motley Fool +33.80%
05:05PM  Why Portola Pharmaceuticals, Caesars Entertainment, and Cal-Maine Foods Jumped Today at Motley Fool
03:18PM  [$$] Portola Shares Surge on Application Acceptance at The Wall Street Journal
02:12PM  Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban GlobeNewswire
Dec-22-16 04:07PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an O
Dec-21-16 09:56AM  Portola Pharmaceuticals, Inc. Value Analysis (NASDAQ:PTLA) : December 21, 2016
Dec-20-16 10:36AM  Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA) at Insider Monkey
07:20AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : December 20, 2016
Dec-19-16 12:20PM  Portola Pharma Wins on Pfizer and Bristol-Myers Loan Agreement +7.55%
08:00AM  Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa (andexanet alfa) GlobeNewswire
Dec-15-16 05:18PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-06-16 11:10AM  Is Portola Pharmaceuticals Inc (PTLA) Worthy of Your Portfolio? at Insider Monkey
Dec-02-16 03:46PM  3 Small-Cap Biotech Stocks That Could Double in 2017 at Motley Fool
Nov-28-16 08:00AM  Portola Pharmaceuticals Announces AndexXa (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-17-16 01:04PM  PORTOLA PHARMACEUTICALS INC Financials
Nov-14-16 04:15PM  Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban GlobeNewswire
Nov-08-16 03:32AM  Edited Transcript of PTLA earnings conference call or presentation 7-Nov-16 9:30pm GMT -12.87%
Nov-07-16 06:06PM  Portola Pharmaceuticals posts 3Q loss +5.67%
04:30PM  Portola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:29PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:05PM  Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions 2016 GlobeNewswire
07:07AM  Q3 2016 Portola Pharmaceuticals Inc Earnings Release - After Market Close
Nov-02-16 08:00AM  Portola Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference GlobeNewswire
Nov-01-16 08:00AM  Portola Pharmaceuticals Expands Clinical Collaboration Agreement with Daiichi Sankyo Worth Up to $25 Million to Develop AndexXa (andexanet alfa) in Germany GlobeNewswire
Oct-31-16 08:00AM  Portola Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Monday, November 7 GlobeNewswire -9.24%
Oct-25-16 08:00AM  Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients GlobeNewswire
Oct-13-16 06:07PM  Portola Pharmaceuticals Supports World Thrombosis Day Campaign to Increase Awareness of Risks of Blood Clots GlobeNewswire
Sep-27-16 09:54AM  3 Stocks That Could Make You Rich at Motley Fool
Sep-20-16 03:01PM  Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy at Motley Fool
11:57AM  Portola Pharmaceuticals, Inc. Value Analysis (NASDAQ:PTLA) : September 20, 2016
Sep-19-16 03:00PM  After Losing Medivation, Who Is Gilead Going After Next? at Forbes
08:12AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : September 19, 2016
Sep-16-16 09:00PM  Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
Sep-13-16 10:50AM  ETFs with exposure to Portola Pharmaceuticals, Inc. : September 13, 2016
08:00AM  Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa (andexanet alfa) at Neurocritical Care Society 2016 Annual Meeting GlobeNewswire
Sep-03-16 02:50PM  3 Biotech Stocks to Buy in September at Motley Fool
Aug-31-16 04:35PM  What Gives With Portola Pharmaceuticals? at Motley Fool
02:54PM  Heres Why Smart Money Investors Are Betting on Portola Pharmaceuticals at Insider Monkey
08:35AM  What's Up With Mylan's EpiPen Pricing? at Motley Fool
Aug-30-16 04:01AM  Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4 Study of Factor Xa Inhibitor Antidote AndexXa (andexanet alfa) in Patients with Acute Major Bleeding GlobeNewswire
Aug-26-16 08:00AM  Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA-4 Study of AndexXa (andexanet alfa) at European Society of Cardiology 2016 Congress GlobeNewswire
Aug-24-16 02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug-22-16 07:48AM  Portola IndexXa's Regulatory Application Validated in the EU
Aug-21-16 10:05AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
08:38AM  3 Stocks That Could Double Your Money at Motley Fool
Aug-19-16 05:32PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:47PM  Portola Pharmaceuticals (PTLA) Stock Falls, Citi Downgrades
11:45AM  Portola's AndexXa Still Approvable, But It Will Take Time
10:06AM  Citi Sees 'Too Much Risk' In Portola Pharma, Downgrades To Neutral
08:30AM  Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa (andexanet alfa), a Factor Xa Inhibitor Antidote GlobeNewswire
Aug-18-16 04:40PM  Is It "Game Over" After Portola's FDA Rejection? at Motley Fool -15.07%
12:05PM  Portola Pharmaceuticals (PTLA) Stock Slumps on FDA Complete Response Letter
11:50AM  Thursdays Top Health Care Stocks Punishing Investors at 24/7 Wall St.
11:21AM  Portola Pharmaceuticals Inc (PTLA): A Misinterpretation Discount? at Insider Monkey
11:06AM  Why Portola Pharmaceuticals Inc Is Plunging Today at Motley Fool
10:38AM  Managing Your Swing Positions/Trades Better
10:16AM  Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.
09:59AM  Portola Pharma plummets 21% after government fails to accept new drug at MarketWatch
08:16AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : August 18, 2016
12:22AM  Portola's AndexXa fails to get US FDA approval Reuters
Aug-17-16 10:57PM  Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa (andexanet alfa) GlobeNewswire -10.97%
Aug-15-16 10:44AM  ETFs with exposure to Portola Pharmaceuticals, Inc. : August 15, 2016
Aug-13-16 09:00AM  3 Under-the-Radar Healthcare Stocks You've Never Heard of at Motley Fool
Aug-12-16 10:25AM  Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-10-16 06:34AM  Portola Pharmaceuticals posts 2Q loss
01:58AM  Edited Transcript of PTLA earnings conference call or presentation 9-Aug-16 8:30pm GMT
Aug-09-16 04:30PM  Portola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:29PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:05PM  Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q2 2016 Portola Pharmaceuticals Inc Earnings Release - Time Not Supplied
Aug-02-16 04:05PM  Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9 GlobeNewswire
Jul-27-16 08:12AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : July 27, 2016
Jul-25-16 02:29PM  Two Under The Radar Biotech Decisions To Watch Next Month at Insider Monkey
Jul-23-16 10:41AM  These 3 Biotechs Have Automatic Demand at Motley Fool
Jul-22-16 12:13PM  Six Major Biotech Acquisitions You Could See in 2016 (Part 2) at Forbes
Jul-11-16 01:27PM  3 Stocks to Buy Near Their 52-Week Lows at Motley Fool
Jun-22-16 04:20PM  PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-21-16 08:03AM  These 5 Biotech Stocks Are Ridiculously Cheap at Motley Fool
Jun-20-16 03:06PM  ETFs with exposure to Portola Pharmaceuticals, Inc. : June 20, 2016
Jun-17-16 08:22AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : June 17, 2016
Jun-01-16 12:50PM  Important Catalysts Approaching for These Biotechs at Investopedia
08:00AM  Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings GlobeNewswire
May-31-16 04:05PM  Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference GlobeNewswire
May-28-16 09:40AM  Portola Pharmaceuticals: Does New Data Get It Back on Track? at Motley Fool
May-27-16 09:54AM  Portola Pharmaceuticals Reveals Full Results Of Final Stage APEX Trial Of Betrixaban
08:45AM  Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting GlobeNewswire
May-23-16 08:00AM  Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting GlobeNewswire
May-21-16 09:40AM  Here's What Pfizer's Telling Us About Biotech M&A at Motley Fool
May-17-16 08:28AM  Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : May 17, 2016
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral, once-daily Factor Xa inhibitor, which is in Phase III clinical trial for treating venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge; and Andexanet alfa, a recombinant protein that is designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase (Syk) and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Lee's Pharmaceutical (HK) Ltd.; and Daiichi Sankyo Company, Limited. The company was founded in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dier MardiExecutive VP and CFOAug 01Option Exercise3.3015,15250,00215,152Aug 01 08:39 PM
Lis WilliamChief Executive OfficerMay 02Sale23.865,675135,40618,333May 03 07:23 PM